They evaluated the intratumor pharmacokinetics using PID imaging analysis, which can assess the distribution of proteins to tumor target sites at the microlevel, to analyze the intratumor distribution of a novel HER2-targeted antibody drug conjugate, trastuzumab deruxtecan (32). This evidence concerns the gene ERBB2 and neoplasm.